GlassScriptPhysician profile
Robert Avilla
NPI 1346687225
$21,594.21
in general payments reported to CMS, 2019-2025
67 companies · $3,130 in 2025
The $3,130 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,027 · 2020: $3,025 · 2021: $3,527 · 2022: $3,318 · 2023: $2,986 · 2024: $2,581 · 2025: $3,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,697.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,066.65 | 2019-2025 | Ubrelvy, Linzess, Qulipta |
| Novo Nordisk INC | $2,587.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $2,435.64 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $1,684.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,406.30 | 2019-2025 | Fasenra, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,080.25 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $934.29 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $870.38 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $624.65 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Allergan, INC. | $579.02 | 2019-2020 | |
| Corcept Therapeutics | $553.76 | 2020-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.69 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Biohaven Pharmaceutical Holding Company LTD. | $393.19 | 2022 | |
| Merck Sharp & Dohme LLC | $321.34 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Biohaven Pharmaceuticals, INC. | $275.63 | 2020-2021 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Avilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.